Hangzhou Bangshun Pharmaceutical

Hangzhou Bangshun Pharmaceutical Co., Ltd. is a biomedical technology company established in 2020 and based in Hangzhou, China. The company focuses on the research and development of molecular targeting and antibody drugs to address conditions in oncology, autoimmune diseases, and inflammatory diseases. Its business model is centered on the clinical development and production of pharmaceuticals, operating through a business scope that includes licensed pharmaceutical production.

The company's drug pipeline includes products at various stages of clinical trials. One of its key products, Bangsairuini, has completed a phase III clinical study for applications in myeloproliferative neoplasms and other blood diseases. Another drug in development, Bangsatini, targets autoimmune diseases such as immune thrombocytopenia (ITP). Hangzhou Bangshun Pharmaceutical actively engages in clinical trials to evaluate the efficacy and safety of its treatments. The firm's technology platforms include small molecule drugs, monoclonal antibodies, and antibody-drug conjugates (ADC).

Since its founding, the company has secured multiple rounds of funding, including a Series B+ in October 2023 and a Series C+ in May 2025, from investors such as Sinowisdom, Shenzhen Capital Real Estate Fund, ZJKF Capital Management, and Puhua Capital. This investment supports its clinical operations, which have branches in Hangzhou, Chengdu, Changsha, and Zhengzhou, and its extensive patent portfolio, which includes 40 patents.

Keywords: molecular targeting drugs, antibody drugs, biopharmaceutical, oncology treatment, autoimmune disease therapy, inflammatory diseases, clinical trials, small molecule drugs, monoclonal antibody, antibody-drug conjugate, myeloproliferative neoplasms, immune thrombocytopenia, pharmaceutical research, drug development, biotechnology, China pharmaceuticals, clinical-stage company, cancer therapy, genetics, biopharma